Bristol-Myers Squibb's (BMY) Breyanzi Significantly Improves Outcomes, Showing Superiority Over 20-Year Standard of Care in Second-Line Relapsed or Refractory Large B-cell Lymphoma Based on TRANSFORM

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/3/2026

1. KRG
2. PBA
3. ALAR
4. CCH:LN
5. META
6. CCHGY
7. PRY:IM
8. PRYMY
9. SPY
10. SKA-B

Go back to Bristol-Myers Squibb's (BMY) Breyanzi Significantly Improves Outcomes, Showing Superiority Over 20-Year Standard of Care in Second-Line Relapsed or Refractory Large B-cell Lymphoma Based on TRANSFORM

Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) Significantly Improves Outcomes, Showing Superiority Over 20-Year Standard of Care in Second-Line Relapsed or Refractory Large B-cell Lymph

December 11, 2021 8:30 AM EST

Phase 3 TRANSFORM study shows Breyanzi significantly improved event-free survival (EFS) vs. chemotherapy plus autologous stem cell transplant, with a 65% reduction in risk of EFS events in first disclosure of results presented at ASH 2021

Breyanzi showed a... More